149 related articles for article (PubMed ID: 8108117)
1. Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt's lymphoma cell lines.
Albert T; Urlbauer B; Kohlhuber F; Hammersen B; Eick D
Oncogene; 1994 Mar; 9(3):759-63. PubMed ID: 8108117
[TBL] [Abstract][Full Text] [Related]
2. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas.
Bhatia K; Huppi K; Spangler G; Siwarski D; Iyer R; Magrath I
Nat Genet; 1993 Sep; 5(1):56-61. PubMed ID: 8220424
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential.
Henriksson M; Bakardjiev A; Klein G; Lüscher B
Oncogene; 1993 Dec; 8(12):3199-209. PubMed ID: 8247524
[TBL] [Abstract][Full Text] [Related]
4. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.
Bemark M; Neuberger MS
Oncogene; 2000 Jul; 19(30):3404-10. PubMed ID: 10918597
[TBL] [Abstract][Full Text] [Related]
5. A potential role for antigen selection in the clonal evolution of Burkitt's lymphoma.
Jain R; Roncella S; Hashimoto S; Carbone A; Francia di Celle P; Foa R; Ferrarini M; Chiorazzi N
J Immunol; 1994 Jul; 153(1):45-52. PubMed ID: 8207254
[TBL] [Abstract][Full Text] [Related]
6. Functional analysis of Burkitt's lymphoma mutant c-Myc proteins.
Smith-Sørensen B; Hijmans EM; Beijersbergen RL; Bernards R
J Biol Chem; 1996 Mar; 271(10):5513-8. PubMed ID: 8621409
[TBL] [Abstract][Full Text] [Related]
7. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift.
Strobl LJ; Kohlhuber F; Mautner J; Polack A; Eick D
Oncogene; 1993 Jun; 8(6):1437-47. PubMed ID: 8502472
[TBL] [Abstract][Full Text] [Related]
8. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
Jochner N; Eick D; Zimber-Strobl U; Pawlita M; Bornkamm GW; Kempkes B
EMBO J; 1996 Jan; 15(2):375-82. PubMed ID: 8617212
[TBL] [Abstract][Full Text] [Related]
10. Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53.
Ramqvist T; Magnusson KP; Wang Y; Szekely L; Klein G; Wiman KG
Oncogene; 1993 Jun; 8(6):1495-500. PubMed ID: 8502475
[TBL] [Abstract][Full Text] [Related]
11. Clustered mutations in the second exon of the MYC gene in sporadic Burkitt's lymphoma.
Yano T; Sander CA; Clark HM; Dolezal MV; Jaffe ES; Raffeld M
Oncogene; 1993 Oct; 8(10):2741-8. PubMed ID: 8397370
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc.
Boffa LC; Cutrona G; Cilli M; Matis S; Damonte G; Mariani MR; Millo E; Moroni M; Roncella S; Fedeli F; Ferrarini M
Cancer Gene Ther; 2007 Feb; 14(2):220-6. PubMed ID: 17053816
[TBL] [Abstract][Full Text] [Related]
13. Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability.
Starczynowski DT; Reynolds JG; Gilmore TD
Oncogene; 2005 Nov; 24(49):7355-68. PubMed ID: 16027730
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of c-Myc and cell immortalization alters c-Myc phosphorylation.
Lutterbach B; Hann SR
Oncogene; 1997 Feb; 14(8):967-75. PubMed ID: 9050996
[TBL] [Abstract][Full Text] [Related]
15. Expression of P0- and P3-RNA from the normal and translocated c-myc allele in Burkitt's lymphoma cells.
Eick D; Polack A; Kofler E; Lenoir GM; Rickinson AB; Bornkamm GW
Oncogene; 1990 Sep; 5(9):1397-402. PubMed ID: 2216463
[TBL] [Abstract][Full Text] [Related]
16. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
Habel ME; Lemieux R; Jung D
J Cell Physiol; 2005 Apr; 203(1):277-85. PubMed ID: 15468060
[TBL] [Abstract][Full Text] [Related]
17. N and C-terminal sub-regions in the c-Myc transactivation region and their joint role in creating versatility in folding and binding.
Fladvad M; Zhou K; Moshref A; Pursglove S; Säfsten P; Sunnerhagen M
J Mol Biol; 2005 Feb; 346(1):175-89. PubMed ID: 15663936
[TBL] [Abstract][Full Text] [Related]
18. Functional interaction of the c-Myc transactivation domain with the TATA binding protein: evidence for an induced fit model of transactivation domain folding.
McEwan IJ; Dahlman-Wright K; Ford J; Wright AP
Biochemistry; 1996 Jul; 35(29):9584-93. PubMed ID: 8755740
[TBL] [Abstract][Full Text] [Related]
19. Dok1 expression and mutation in Burkitt's lymphoma cell lines.
Lee S; Huang H; Niu Y; Tommasino M; Lenoir G; Sylla BS
Cancer Lett; 2007 Jan; 245(1-2):44-50. PubMed ID: 16338067
[TBL] [Abstract][Full Text] [Related]
20. Lack of mutagenicity and clastogenicity of PNAEmu-NLS targeted to a regulatory sequence of the translocated c-myc oncogene in Burkitt's lymphoma.
Boffa LC; Menichini P; Bolognesi C; Cutrona G; Roncella S; Damonte GL; Millo E; Mariani MR; Matis S; Russo D; Ciliutti P; Ferrarini M
Mutat Res; 2007 Apr; 628(2):129-37. PubMed ID: 17267263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
